SG10201809450VA - Heterogeneous polypeptide expression cassette - Google Patents

Heterogeneous polypeptide expression cassette

Info

Publication number
SG10201809450VA
SG10201809450VA SG10201809450VA SG10201809450VA SG10201809450VA SG 10201809450V A SG10201809450V A SG 10201809450VA SG 10201809450V A SG10201809450V A SG 10201809450VA SG 10201809450V A SG10201809450V A SG 10201809450VA SG 10201809450V A SG10201809450V A SG 10201809450VA
Authority
SG
Singapore
Prior art keywords
bacterium
expression cassette
heterogeneous polypeptide
genus bifidobacterium
heterogeneous
Prior art date
Application number
SG10201809450VA
Inventor
Koichi Koseki
Takeshi Masaki
Koichiro Shioya
Hitomi Shimizu
Masao Tsukamoto
Satoshi Kobayashi
Tomio Matsumura
Yuko Shimatani
Original Assignee
Anaeropharma Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaeropharma Science Inc filed Critical Anaeropharma Science Inc
Publication of SG10201809450VA publication Critical patent/SG10201809450VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element

Abstract

HETEROGENEOUS POLYPEPTIDE EXPRESSION CASSETTE An object is to provide a signal peptide that can secrete a heterogeneous polypeptide with high efficiency outside the bacterial cell in a bacterium of the genus Bifidobacterium, an expression cassette that can secrete a heterogeneous polypeptide with high efficiency outside the bacterial cell, a heterogeneous polypeptide expression vector, a bacterium of the genus Bifidobacterium capable of secreting a heterogeneous polypeptide. Means for attaining the object is a bacterium of the genus Bifidobacterium transformed by a vector having an expression cassette sequentially comprising a promoter DNA functioning in a bacterium of the genus Bifidobacterium, a DNA encoding the secretory signal peptide, a DNA encoding a scFv antibody having an antitumor activity, and a terminator DNA functioning in the bacterium of the genus Bifidobacterium; and capable of secreting the scFv antibody with high efficiency outside the bacterial cell. [No suitable Figure]
SG10201809450VA 2014-05-01 2015-04-17 Heterogeneous polypeptide expression cassette SG10201809450VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014094869 2014-05-01

Publications (1)

Publication Number Publication Date
SG10201809450VA true SG10201809450VA (en) 2018-11-29

Family

ID=54358386

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201809450VA SG10201809450VA (en) 2014-05-01 2015-04-17 Heterogeneous polypeptide expression cassette
SG11201609032WA SG11201609032WA (en) 2014-05-01 2015-04-17 Heterogeneous polypeptide expression cassette

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201609032WA SG11201609032WA (en) 2014-05-01 2015-04-17 Heterogeneous polypeptide expression cassette

Country Status (8)

Country Link
US (1) US10443061B2 (en)
EP (1) EP3141602A4 (en)
JP (1) JP6634625B2 (en)
KR (1) KR20170002403A (en)
CN (1) CN107002090B (en)
CA (1) CA2947525C (en)
SG (2) SG10201809450VA (en)
WO (1) WO2015166640A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2947529C (en) 2014-05-02 2022-06-21 Shinshu University Antibody gene expression-secretion system
DK3228706T3 (en) * 2014-12-03 2021-07-26 Azusapharma Sciences Inc COEKSPRESSION PLASMID
SG11201705915VA (en) 2015-01-19 2017-08-30 Univ Shinshu Therapeutic agent for ischemic diseases
EP3402498A1 (en) * 2016-01-11 2018-11-21 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
BR112019013863A2 (en) 2017-01-06 2020-03-03 Synlogic Operating Company, Inc. MICRO-ORGANISMS PROGRAMMED TO PRODUCE IMMUNE AND ANTICANCER THERAPEUTIC MODULATORS IN TUMOR CELLS
US20220281998A1 (en) 2019-08-28 2022-09-08 Azusapharma Sciences, Inc. Bifidobacterium spp. expressing and secreting diabody-type bsab
CN110747154A (en) * 2019-09-17 2020-02-04 广州维生君生物科技有限公司 PD-1 humanized single-chain antibody fusion gene transformed lactic acid bacteria and application thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
DE10101793A1 (en) * 2001-01-17 2002-08-01 Manfred Nilius Use of SLPI to treat inflammatory bowel disease
EP1227152A1 (en) 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
US20040241745A1 (en) * 2001-07-31 2004-12-02 Tasuku Honjo Substance specific to pd-1
KR101302088B1 (en) * 2005-04-08 2013-08-30 가부시키가이샤 아네로파마·사이엔스 5-fluorouracil-resistant bacteria and method for production thereof
US9730968B2 (en) * 2008-04-17 2017-08-15 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
WO2010126073A1 (en) 2009-04-28 2010-11-04 協和発酵キリン株式会社 Expression cassette for secretion/expression of polypeptide, and use thereof
CN101608172B (en) * 2009-07-24 2013-01-23 南京华贞生物医药科技有限公司 Transformant for reducing weight and fat and preparation method thereof
CA2787787A1 (en) * 2010-01-29 2011-08-04 Anaeropharma Science, Inc. Transformation plasmid
KR20150037953A (en) 2012-07-13 2015-04-08 각코호진 데이쿄 헤이세이 다이가쿠 Anti-tumour agent, marker for tumour detection, and oral vaccine agent

Also Published As

Publication number Publication date
WO2015166640A1 (en) 2015-11-05
EP3141602A1 (en) 2017-03-15
CN107002090A (en) 2017-08-01
EP3141602A4 (en) 2017-11-29
US10443061B2 (en) 2019-10-15
KR20170002403A (en) 2017-01-06
CA2947525A1 (en) 2015-11-05
JPWO2015166640A1 (en) 2017-04-20
JP6634625B2 (en) 2020-01-22
CA2947525C (en) 2023-09-05
US20170183667A1 (en) 2017-06-29
SG11201609032WA (en) 2016-12-29
CN107002090B (en) 2021-09-10

Similar Documents

Publication Publication Date Title
SG10201809450VA (en) Heterogeneous polypeptide expression cassette
EP3303403A4 (en) Delivery of structurally diverse polypeptide cargo into mammalian cells by a bacterial toxin
WO2019046766A3 (en) End-to-end cell therapy automation
MY181199A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
IL230750B (en) Ground robot drive system
MY176294A (en) Antibodies comprising chimeric constant domains
MX2018014043A (en) Cell culture compositions with antioxidants and methods for polypeptide production.
PH12014501476A1 (en) Systems and methods to transmit configuration change messages between an access point and a station
MX2019003427A (en) Cell culture compositions and methods for polypeptide production.
MX2015010427A (en) Highly galactosylated anti-tnf-alpha antibodies and uses thereof.
MX2015012487A (en) Control of growth-induction-production phases.
MX2014008441A (en) Clostridium histolyticum enzymes and methods for the use thereof.
MX2016015214A (en) Apparatus and method.
MX2016000634A (en) Optimised method for breaking chlorella cell walls by means of very high pressure homogenisation.
EA201592169A1 (en) RECOMBINANT MICROORGANISMS WHICH ARE INCREASING A FLOW THROUGH THE ENZYMING WAY
MX2016013849A (en) A protein secretory factor with high secretory efficiency and an expression vector comprising the same.
MY168287A (en) Cow rumen xylose isomerases active in yeast cells
AU2015348922A8 (en) Codon optimized polynucleotide for high level expression of CRM197
MX2013008984A (en) Streamer coating device and method.
EP3230457A4 (en) Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
PH12017500047A1 (en) Dual cistronic bacterial expression system
MY172019A (en) Bacterial xylose isomerases active in yeast cells
EP3511409A4 (en) Salt-tolerant lactobacillus, method of culturing salt-tolerant lactobacillus, and immunostimulant
MX2016002651A (en) Modified microorganism for improved production of alanine.
EP3162891A4 (en) Cultured cell differentiation promotion method and cultured cell differentiation promoter